Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

Download PDF Copy

Jun 3 2011

iBio, Inc. (NYSE AMEX: IBIO) today announced positive interim results from a Phase 1 clinical trial of an iBioLaunch™ platform-produced subunit vaccine directed against Influenza A/California/04/09 (H1N1). The vaccine demonstrated strong induction of dose correlated immune responses, with or without adjuvant, as assessed by virus microneutralization antibody assays and hemagglutination inhibition (HAI) responses. The vaccine was safe and well tolerated at all doses when administered with and without adjuvant.

"These expected positive results are an important confirmation of the utility of the iBioLaunch platform, not only for rapid response to infectious disease challenges such as influenza, but also as a preferred approach to a broad range of vaccine and therapeutic products," said Robert Kay, iBio's Chairman and Chief Executive Officer.

Source: iBio, Inc.

Posted in: Drug Trial News | Disease/Infection News

Tags: Antibody, Biotechnology, Clinical Trial, Gene, Gene Expression, H1N1, Healthcare-Associated Infection HAI, Immune System, Infectious Diseases, Influenza, Pandemic, Placebo, Vaccine, Virology, Virus

Comments (0)

Download PDF Copy

Suggested Reading

Bivalent COVID-19 vaccine boosts immunity but needs to be updated

Bivalent COVID-19 vaccine boosts immunity but needs to be updated

Study rethinks immune system strategies to boost vaccine effectiveness

Study rethinks immune system strategies to boost vaccine effectiveness

The path to a better tuberculosis vaccine runs through Montana

The path to a better tuberculosis vaccine runs through Montana

Nigeria first to rollout new Men5CV vaccine against meningitis

Nigeria first to rollout new Men5CV vaccine against meningitis

Seasonal influenza triggers significant school closures, especially in southern states, study finds

Seasonal influenza triggers significant school closures, especially in southern states, study finds

Annual COVID-19 vaccine proves to be a wise investment for personal health and pocketbook

Annual COVID-19 vaccine proves to be a wise investment for personal health and pocketbook

New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses

New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses

MSU team creates a promising vaccine candidate for antibiotic-resistant bacteria

MSU team creates a promising vaccine candidate for antibiotic-resistant bacteria

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Researchers identify key barriers and outline recommendations for vaccine uptake in pregnant women